Pharmacological Inhibition of C-C Chemokine Receptor 2 Decreases Macrophage Infiltration in the Aortic Root of the Human C-C Chemokine Receptor 2/Apolipoprotein E-/- Mouse: Magnetic Resonance Imaging Assessment

被引:37
|
作者
Olzinski, Alan R. [1 ]
Turner, Gregory H. [1 ]
Bernard, Roberta E. [1 ]
Karr, Heather [1 ]
Cornejo, Carla A. [1 ]
Aravindhan, Karpagam [1 ]
Hoang, Bao [2 ]
Ringenberg, Michael A. [3 ]
Qin, Pu [1 ]
Goodman, Krista B. [1 ]
Willette, Robert N. [1 ]
Macphee, Colin H. [1 ]
Jucker, Beat M. [1 ]
Sehon, Clark A. [1 ]
Gough, Peter J. [1 ]
机构
[1] Cardiovasc & Urogenital Ctr Excellence Drug Disco, King Of Prussia, PA USA
[2] Discovery Technol Grp, King Of Prussia, PA USA
[3] GlaxoSmithKline, Safety Assessment, King Of Prussia, PA USA
关键词
Atherosclerosis; Inflammation; Magnetic Resonance Imaging; USPIO; ApoE(-/-) CCR2; ULTRASMALL SUPERPARAMAGNETIC PARTICLES; E-DEFICIENT MICE; IRON-OXIDE PARTICLES; ATHEROSCLEROTIC PLAQUES; ANGIOTENSIN-II; IN-VIVO; REDUCES ATHEROSCLEROSIS; HYPERLIPIDEMIC RABBITS; LESION FORMATION; CCR2; ANTAGONIST;
D O I
10.1161/ATVBAHA.109.198812
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose-This study assessed the pharmacological effect of a novel selective C-C chemokine receptor (CCR) 2 antagonist (GSK1344386B) on monocyte/macrophage infiltration into atherosclerotic plaque using magnetic resonance imaging (MRI) in an atherosclerotic mouse model. Methods and Results-Apolipoprotein E-/- mice expressing human CCR2 were fed a Western diet (vehicle group) or a Western diet plus10 mg/kg per day of GSK1344386B (GSK1344386B group). After the baseline MRI, mice were implanted with osmotic pumps containing angiotensin II, 1000 ng/kg per minute, to accelerate lesion formation. After five weeks of angiotensin II administration, mice received ultrasmall superparamagnetic iron oxide, an MRI contrast agent for the assessment of monocyte/macrophage infiltration to the plaque, and underwent imaging. After imaging, mice were euthanized, and the heart and aorta were harvested for ex vivo MRI and histopathological examination. After 5 weeks of dietary dosing, there were no significant differences between groups in body or liver weight or plasma cholesterol concentrations. An in vivo MRI reflected a decrease in ultrasmall superparamagnetic iron oxide contrast agent uptake in the aortic arch of the GSK1344386B group (P<0.05). An ex vivo MRI of the aortic root also reflected decreased ultrasmall superparamagnetic iron oxide uptake in the GSK1344386B group and was verified by absolute iron analysis (P<0.05). Although there was no difference in aortic root lesion area between groups, there was a 30% reduction in macrophage area observed in the GSK1344386B group (P<0.05). Conclusion-An MRI was used to noninvasively assess the decreased macrophage content in the atherosclerotic plaque after selective CCR2 inhibition. (Arterioscler Thromb Vasc Biol. 2010; 30: 253-259.)
引用
收藏
页码:253 / U240
页数:16
相关论文
共 50 条
  • [2] C-C chemokine receptor 2 and C-C chemokine receptor 5 genotypes in patients treated for chronic hepatitis C virus infection
    Dorak, MT
    Folayan, GO
    Niwas, S
    van Leeuwen, DJ
    Yee, LJ
    Tang, JM
    Kaslow, RA
    IMMUNOLOGIC RESEARCH, 2002, 26 (1-3) : 167 - 175
  • [3] C-C chemokine receptor 2 and C-C chemokine receptor 5 genotypes in patients treated for chronic hepatitis C virus infection
    M. Tevfik Dorak
    Gbolahan O. Folayan
    Santosh Niwas
    Dirk J. van Leeuwen
    Leland J. Yee
    Jianning Tang
    Richard A. Kaslow
    Immunologic Research, 2002, 26 : 167 - 175
  • [4] A novel activator of C-C chemokine, FROUNT, is expressed with C-C chemokine receptor 2 and its ligand in failing human heart
    Satoh, Mamoru
    Akatsu, Tomonari
    Ishkawa, Yuh
    Minami, Yoshitaka
    Nakamura, Motoyuki
    JOURNAL OF CARDIAC FAILURE, 2007, 13 (02) : 114 - 119
  • [5] A novel activator of C-C chemokine, FROUNT, is expressed with C-C chemokine receptor 2 and its ligand in failing human heart
    Satoh, M.
    Akatsu, T.
    Ishikawa, Y.
    Minami, Y.
    Nakamura, M.
    EUROPEAN JOURNAL OF HEART FAILURE, 2007, 6 : 89 - 89
  • [6] Inhibition of the chemokine (C-C motif) ligand 2/chemokine (C-C motif) receptor 2 pathway attenuates hyperglycaemia and inflammation in a mouse model of hepatic steatosis and lipoatrophy
    Yang, S. J.
    IglayReger, H. B.
    Kadouh, H. C.
    Bodary, P. F.
    DIABETOLOGIA, 2009, 52 (05) : 972 - 981
  • [7] Everolimus Limits Aortic Aneurysm in the Apolipoprotein E-Deficient Mouse by Downregulating C-C Chemokine Receptor 2 Positive Monocytes
    Moran, Corey S.
    Jose, Roby J.
    Moxon, Joseph V.
    Roomberg, Alicia
    Norman, Paul E.
    Rush, Catherine
    Koerner, Heinrich
    Golledge, Jonathan
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2013, 33 (04) : 814 - U410
  • [8] Pharmacological Blockade of C-C Chemokine Receptor 4 Exacerbates Atherosclerosis in Apolipoprotein E-Deficient Mice
    Amin, Hilman Z.
    Sasaki, Naoto
    Horibe, Sayo
    Kawauchi, Shoji
    Matsuo, Kazuhiko
    Nakayama, Takashi
    Rikitake, Yoshiyuki
    Hirata, Ken-Ichi
    CIRCULATION, 2019, 140
  • [9] C-C motif chemokine ligand 2/C-C receptor 2 is associated with glioma recurrence and poor survival
    Yang, Qiuan
    Zhang, Junpeng
    Zhang, Xin
    Miao, Lifeng
    Zhang, Wei
    Jiang, Zheng
    Zhou, Wei
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2021, 21 (06)
  • [10] Cloning and functional characterization of the rabbit C-C chemokine receptor 2
    Lu, DS
    Yuan, XJ
    Evans, RJ
    Pappas, AT
    Wang, H
    Su, EW
    Hamdouchi, C
    Venkataraman, C
    BMC IMMUNOLOGY, 2005, 6 (1)